Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06362759 | A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP | PHASE2 | COMPLETED | 143 | — | — | May 15, 2024 | Dec 4, 2025 | Feb 24, 2026 | 38 | United States |
Evaluates the change from baseline in hs-CRP comparing TOUR006 and placebo
| Arm | Type | Description |
|---|---|---|
| TOUR006 - 50 MG | EXPERIMENTAL | 50 mg administered subcutaneously at Day 1 and Day 90 (Placebo administered at 30, 60, 120, and 150 Day timepoints) |
| TOUR006 - 25 MG | EXPERIMENTAL | 25 mg administered subcutaneously at Day 1 and Day 90 (Placebo administered at 30, 60, 120, and 150 Day timepoints) |
| TOUR006 - 15 MG | EXPERIMENTAL | 15 mg administered subcutaneously at Days 1, 30, 60, 90, 120, and 150 |
| Placebo | PLACEBO_COMPARATOR | Administered subcutaneously at Days 1, 30, 60, 90, 120, and 150 |
| Name | Type | Description |
|---|---|---|
| TOUR006 - 50 MG | DRUG | TOUR006 50 MG |
| TOUR006 - 25 MG | DRUG | TOUR006 25 MG |
| TOUR006 - 15 MG | DRUG | TOUR006 15 MG |
| Placebo | OTHER | Placebo |
Inclusion Criteria: * Age ≥18 years at time of ICF signature. * Serum hs-CRP level ≥2.0 mg/L and \<15 mg/L * Diagnosis of chronic kidney disease, eGFR ≥15 and \<60 mL/min/1.73 m2 or eGFR ≥60 mL/min/1.73m2 and UPCR\>200 mg/g * Received COVID-19 vaccine at least 30 days prior to the Screening visit, ...